Genmab (GMAB)
(Delayed Data from NSDQ)
$27.05 USD
+0.81 (3.09%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $27.03 -0.02 (-0.07%) 7:58 PM ET
2-Buy of 5 2
B Value A Growth C Momentum A VGM
Brokerage Reports
Genmab A/S Sponsored ADR [GMAB]
Reports for Purchase
Showing records 101 - 114 ( 114 total )
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
CASSIOPEIA Regimen Receives European Approval
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
DARZALEX Front-Line Regimen Wins European Thumbs up; Teprotumumab Clears FDA Panel Vote; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
DARZALEX Continues to Deliver Clinical Benefit
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
DARZALEX Sales Cross $2.5B Threshold, Triggering $100M Milestone Payment; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
Tisotumab Vedotin Cervical Cancer Data Incrementally Positive in Our View; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
As Anticipated, DARZALEX Front-Line MAIA Regimen Wins Approval in Europe; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
Numerous ASH Abstracts; 3Q19 Financials Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
CHMP Issues Positive Opinion on DARZALEX Front-Line MAIA Regimen; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
DARZALEX 3Q19 Sales Reported; Reiterate Buy and Raising PT to $25
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
FDA Approves CASSIOPEIA Regimen for 1L Transplant-Eligible Multiple Myeloma Patients; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
ARZERRA Matches OCREVUS; Positive GRIFFIN and CANDOR Data; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
Management Highlights Pipeline at Genmab Breakfast; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
Arzerra Set to Take on Roche''s Ocrevus; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
Converting to US Listing; Reiterate Buy and $24 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R